riociguat - search results

bayer new zealand limited - riociguat 0.5mg - film coated tablet - 0.5 mg - active: riociguat 0.5mg excipient: crospovidone hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

adempas

bayer new zealand limited - riociguat 1mg - film coated tablet - 1 mg - active: riociguat 1mg excipient: crospovidone hyprolose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

adempas

bayer new zealand limited - riociguat 1.5mg - film coated tablet - 1.5 mg - active: riociguat 1.5mg excipient: crospovidone hyprolose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

adempas

bayer new zealand limited - riociguat 2mg - film coated tablet - 2 mg - active: riociguat 2mg excipient: crospovidone hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.